FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 关于上海复旦张江生物医药股份有限公司 2024 年度股东周年大会的法律意见书 致：上海复旦张江生物医药股份有限公司（"复旦张江"或"公司"） 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律 执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席复旦张江 2024 年度股东周年大会（以下简称"本次股东会"），并就本次股东会的召集和召 开程序、参与表决和召集会议人员的资格、表决程序和表决结果等有关事宜出具 本法律意见书。 本法律意见书依据《中华人民共和国公司法》《中 ...

证券代码：688505 证券简称：复旦张江 公告编号：临 2025-019 上海复旦张江生物医药股份有限公司 2024年度股东周年大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 26 日 （二） 股东大会召开的地点：上海市浦东新区碧波路 699 号上海博雅酒店一楼 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 190 | | --- | --- | | 普通股股东人数 | 190 | | 其中：A 股股东人数 | 189 | | 境外上市外资股股东人数 | 1 | | 2、出席会议的股东所持有的表决权数量 | 409,978,047 | | 普通股股东所持有表决权数量 | 409,978,047 | | 其中：A 股股东所持有表决权数量 | 334,983,047 | | 境外上市外资股股东所 ...

Group 1: Fudan Zhangjiang - Shareholders Yang Zongmeng and Wang Haibo plan to reduce their holdings by a total of up to 1.41% of the company's shares [1] - Yang Zongmeng intends to sell up to 10.36 million shares, representing 1.00% of the total share capital [1] - Wang Haibo plans to sell up to 4.27 million shares, representing 0.41% of the total share capital [1] Group 2: Aisen Co., Ltd. - Shareholders including Ailong Venture Capital and executives plan to reduce their holdings by a total of up to 3.86% of the company's shares [1] - Ailong Venture Capital intends to sell up to 2.644 million shares, representing 3.00% of the total share capital [1] - Other executives plan to sell smaller amounts, with individual reductions ranging from 0.17% to 0.45% of the total share capital [1] Group 3: Youyou Food - Actual controller Zhao Ying plans to reduce his holdings by up to 3% of the company's shares [3] - The planned reduction amounts to up to 12.83 million shares [3] Group 4: Chenfeng Technology - The company plans to sell idle assets, including 6 vehicles and 53 pieces of machinery, for a total estimated sale price of 8.1461 million yuan [5] - Expected disposal gains from the sale are approximately 3.6238 million yuan [5] Group 5: *ST Hengtai - The company will cancel its delisting risk warning and other risk warnings, with the stock name changing from "*ST Hengtai" to "Henglitai" [6] - The stock will be suspended for one day and the price fluctuation limit will change to 10% [6] Group 6: Xinyunda - Shareholder Wuku International Trust plans to reduce its holdings by up to 3% of the company's shares [9] - The planned reduction amounts to up to 5.9823 million shares [9] Group 7: Shaoyang Hydraulic - The company is planning a major asset restructuring, which involves issuing shares and cash to acquire part or all of Chongqing Xincheng Hangrui Technology Co., Ltd. [10] - The stock will be suspended for up to 10 trading days [10] Group 8: Xingwang Yuda - The company announced that part of its bank account funds, totaling 25.9335 million yuan, have been frozen [11] - The frozen amount represents 1.42% of the company's most recent audited net assets [11] Group 9: Tianrong Tianyu - Shareholder Yan Xuewei plans to reduce his holdings by up to 3% of the company's shares [12] - The planned reduction amounts to up to 4.2089 million shares [12] Group 10: Qiming Star - The chairman Wei Bing has resigned due to work adjustments at China Mobile Communications Group [13] Group 11: Aosaikang - The company's subsidiary has received a drug registration certificate for Methotrexate injection, which is considered equivalent to passing consistency evaluation [15][16] Group 12: Xinhau Optoelectronics - The company plans to transfer 100% equity of its wholly-owned subsidiary, Xinguang Energy Technology (Anhui) Co., Ltd. [17] Group 13: ST Baili - The company's controlling shareholder has been applied for bankruptcy liquidation due to inability to repay debts [19]

证券代码：688505 证券简称：复旦张江 公告编号：临 2025-018 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 大股东的基本情况 截至本公告披露日，上海复旦张江生物医药股份有限公司（以下简称"公司" 或"复旦张江"）股东杨宗孟先生持有公司股份 74,375,494 股，占公司总股本的 股东所持有的公司股份来源为公司首次公开发行前持有的股份数量，该部分股份 已于 2023 年 6 月 19 日起全部解除限售并上市流通。 ? 减持计划的主要内容 公司于近日分别收到杨宗孟先生、王海波先生发来的《关于减持复旦张江股 份计划的告知函》，因自身资金需求，杨宗孟先生计划自本公告披露之日起 15 个交易日后的 3 个月内通过集中竞价的方式减持公司股份不超过 10,365,721 股， 拟减持比例不超过公司总股本的 1.00%；王海波先生计划自本公告披露之日起 15 个交易日后的 3 个月内通过集中竞价的方式减持公司股份不超 ...

证券代码：688505 证券简称：复旦张江 公告编号：临 2025-018 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 大股东的基本情况 股东名称 杨宗孟 股东身份 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 √是 □否 董事、监事和高级管理人员 □是 √否 其他：无 持股数量 74,375,494股 持股比例 7.18% 当前持股股份来源 IPO 前取得：74,375,494股 截至本公告披露日，上海复旦张江生物医药股份有限公司（以下简称"公司" 或"复旦张江"）股东杨宗孟先生持有公司股份 74,375,494 股，占公司总股本的 7.18%；王海波先生持有公司股份 56,099,327 股，占公司总股本的 5.41%。上述 股东所持有的公司股份来源为公司首次公开发行前持有的股份数量，该部分股份 已于 2023 年 6 月 19 日起全部解除限售并上市流通。 减持计划的主要内容 公司于近日分别收到杨宗孟先生、王 ...

Group 1: Stock Resumption - Bohai Automobile plans to acquire 51% equity in Beiqi Moulding, 51% equity in Langfang Andotuo, 100% equity in Zhilian Technology, and 50% equity in Laini Wiring Harness, with stock resuming trading tomorrow [1] - Bangji Technology intends to purchase 100% equity in Beixi Agriculture, Ruido Weili, Xinmu Agriculture, Ruido Agriculture (Lijin), Ruido Agriculture (Shandong), and Weili Agriculture (Binzhou), as well as 80% equity in Paistong through issuing shares and cash payment, with stock resuming trading [1] Group 2: Mergers and Acquisitions - Taihe Intelligent plans to acquire 100% equity in Sunshine Yuchu for no more than 50 million, aiming to expand its energy storage business for commercial users [2] - Wuzhou Xinchun intends to raise no more than 1 billion for the research and industrialization of embodied intelligent robots and core components for automotive intelligent driving [2] Group 3: Share Buybacks - Zhongtong Bus has initiated its first share buyback of 2 million shares [3] - Midea Group plans to repurchase shares worth between 5 billion to 10 billion [6] Group 4: Investment Cooperation and Business Status - Jiangbolong's subsidiary has signed a cooperation memorandum with SanDisk, a globally recognized storage solutions provider with leading storage technology and extensive system design experience [5] - Dazhu CNC has had its application materials for overseas listing shares accepted by the China Securities Regulatory Commission [7] - SanDa Membrane plans to issue H-shares and list on the Hong Kong Stock Exchange [7] - Xinqi Eye Medicine has enrolled the first subject in the Phase III clinical trial for lidocaine eye gel [7] - Shanshui Technology intends to invest 6 billion in a new chemical materials project [7] - China Energy Construction's subsidiary consortium has won a 5 billion EPC general contracting project [7] - Fudan Zhangjiang's injectable FZ-P001 sodium for visualizing malignant lesions during cancer surgery has received clinical trial application acceptance [7] - Yiyuan Lithium Energy plans to extend the reduction of 3.5% shares in Simor International [7] - Lakala is planning to list on the Hong Kong Stock Exchange to accelerate the application of digital currency in cross-border scenarios [7] - Jintaiyang intends to cancel 1.7692 million shares and reduce registered capital accordingly [8] - Aiwei Electronics has developed a low-power high-voltage piezoelectric micro-pump liquid cooling product, marking a breakthrough in domestic chip technology in this field [8] - Redik plans to acquire investment fund shares worth 40 million, focusing on strengthening technology reserves for key components like robotic joint modules [9]

股票代码：688505 股票简称：复旦张江 编号：临 2025-017 上海复旦张江生物医药股份有限公司 自愿披露关于注射用 FZ-P001 钠用于癌症术中恶性病变可视化 获得药物临床试验申请受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）于近日收到国家药 品监督管理局核准签发的《受理通知书》，注射用 FZ-P001 钠（以下简称"该药 物"）用于癌症术中恶性病变可视化的 I 期临床试验申请获得受理。由于药品的 研发周期长、审批环节多，容易受到一些不确定性因素的影响，敬请广大投资者 谨慎决策，注意防范投资风险。现将相关情况公告如下： 一、药物的基本情况 受 理 号：CXHL2500576 申 请 人：上海复旦张江生物医药股份有限公司 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 由于医药产品具有高科技、高风险、高附加值的特点，药品从临床前研究、 临床试验到商业化的周期长、环节多，容易受到一些不确定性因素的影响。敬请 ...

Core Viewpoint - Fudan Zhangjiang has received the acceptance notice from the National Medical Products Administration for its self-developed injectable FZ-P001 sodium, aimed at visualizing malignant lesions during cancer surgery, marking a significant step in the development of innovative surgical solutions for tumor removal [1] Company Summary - The injectable FZ-P001 sodium is classified as a Class 1 new chemical drug, with its active ingredient being a conjugate of folate receptor-targeting small molecules and photosensitizers [1] - The drug is intended to enhance the effectiveness of surgical resection of solid tumors by indicating the presence of malignant tissue and the status of surgical margins [1] - This marks the first human Phase I clinical trial application for the drug, focusing on evaluating its safety, tolerability, and pharmacokinetic characteristics in humans [1] Industry Summary - The development of FZ-P001 sodium represents an innovative approach in the field of oncology, particularly in improving surgical outcomes for cancer patients [1] - The approval for the clinical trial reflects the growing interest and investment in advanced therapeutic solutions within the pharmaceutical industry [1]

上海众辰电子科技股份有限公司 上海众辰电子科技股份有限公司（以下简称"公司"）为了进一步建立、健 全公司长效激励机制，吸引和留住优秀人才，充分调动公司员工的积极性，有效 地将股东利益、公司利益和核心团队个人利益结合在一起，使各方共同关注公司 的长远发展，在充分保障股东利益的前提下，按照收益与贡献对等的原则，实施 为保证本激励计划的顺利实施，现根据《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司股权激励管理办法》等有关法律、法规和规范性文 件以及《上海众辰电子科技股份有限公司章程》（以下简称《公司章程》）《2025 年第二期限制性股票激励计划（草案）》（以下简称《激励计划（草案）》）的 相关规定，并结合公司的实际情况，特制定本办法。 四、考核机构 公司行政部按照本办法及董事会薪酬与考核委员会的考核安排负责具体实 施对个人的绩效考核。公司财务部按照本办法及董事会薪酬与考核委员会的考核 安排负责具体实施对公司的业绩考核。行政部、财务部对考核数据和考核结果的 真实性、准确性、完整性和及时性负责，向董事会薪酬与考核委员会报告考核结 果，接受董事会薪酬与考核委员会关于考核结果的质询。 董事会薪酬与考核委员会主 ...

Core Viewpoint - Fudan Zhangjiang faces significant challenges due to a price adjustment of its key oncology drug, resulting in a projected revenue decline and potential losses for the product in 2025 [1][2][6]. Group 1: Price Adjustment Impact - The retail price of the oncology drug, Liposomal Doxorubicin (brand name: Liboduo), has been reduced by at least 35% effective May 1, 2024, due to its inclusion in the national centralized procurement list [1][5][6]. - The price adjustment is expected to lead to a more than 50% decline in sales revenue for Liboduo in 2025, raising concerns about the product potentially incurring losses [2][6]. Group 2: Financial Performance - Fudan Zhangjiang's revenue and net profit have declined for three consecutive years from 2022 to 2024, with 2024 projected revenues of 709 million yuan, down 16.61% year-on-year [2][8]. - The company reported a net profit margin of only 5.56% in 2024, significantly lower than the 21.44% in 2019, primarily due to high R&D and sales expenses [10]. Group 3: R&D Investments - Despite declining revenues, Fudan Zhangjiang has increased its R&D investment to 314 million yuan in 2024, accounting for 44.29% of its total revenue, indicating a commitment to innovation [9][10]. - The company is advancing several projects, including antibody-drug conjugates, with ongoing clinical trials and new production facilities [9]. Group 4: Market Performance - Since its listing in July 2020, Fudan Zhangjiang's stock price has dropped over 80%, from a peak of 42.35 yuan per share to 7.83 yuan as of April 30, 2024 [4][11].